ReviewFrontiers in immunology2019
The BTLA-HVEM-CD5 Immunoregulatory Axis-An Instructive Mechanism Governing pTreg Cell Differentiation.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Beyond PD-L1/PD-1: expression of PVR/TIGIT and TNFRSF14/BTLA axes in response to Helicobacter pylori and in gastric cancer lesions.ImmunoHorizons · 2026Article
- Recombinant Antibody Vaccines for Targeted Antigen Delivery: Design Principles and Immunological Applications.Vaccines · 2026Review
- Comparative proteomic and lipidomic analysis of yak and bovine buttermilk fat globule membranes: Insights into nutritional and functional differences.Food chemistry: X · 2026Article
- BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Aberrant Expression ofCancers · 2025Article
- Causal role of immune cells in IgA nephropathy: a mendelian randomization study.Renal failure · 2024Article
- Causal role of the pyrimidine deoxyribonucleoside degradation superpathway mediation in Guillain-Barré Syndrome via the HVEM on CD4 + and CD8 + T cells.Scientific reports · 2024Article
- Emerging T cell immunoregulatory mechanisms in multiple sclerosis and Alzheimer's disease.Frontiers in aging neuroscience · 2024Review
- Activation, Amplification, and Ablation as Dynamic Mechanisms of Dendritic Cell Maturation.Biology · 2023Review
- B and T lymphocyte attenuator as a C-reactive protein and IgA associated auxiliary diagnostic marker for pulmonary tuberculosis: a case-control study.Annals of translational medicine · 2022Article
- TNF-α sculpts a maturation process in vivo by pruning tolerogenic dendritic cells.Cell reports · 2022Article
- Variegated Outcomes of T Cell Activation by Dendritic Cells in the Steady State.Journal of immunology (Baltimore, Md. : 1950) · 2022Review
- Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo.Antibodies (Basel, Switzerland) · 2022Review
- Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy.Frontiers in immunology · 2022Review
- The formation of pre-effectors in the steady state opens a new perspective for cancer immunosurveillance.Oncotarget · 2021Article
- A Two-Step Process of Effector Programming Governs CD4Cell reports · 2020Article
- Targeting Dendritic Cells with Antigen-Delivering Antibodies for Amelioration of Autoimmunity in Animal Models of Multiple Sclerosis and Other Autoimmune Diseases.Antibodies (Basel, Switzerland) · 2020Review
- Natural and Induced Tolerogenic Dendritic Cells.Journal of immunology (Baltimore, Md. : 1950) · 2020Review
- Reduced CD5 on CD8Frontiers in immunology · 2020Article
- Current and Future Immunotherapies for Multiple Sclerosis.Missouri medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.